Vera Cappelletti

List of Publications by Year
in descending order

86	2,389	236612 25	233125 45
papers	citations	h-index	g-index

87	87	87	3678
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1993, 85, 965-970.	3.0	226
2	The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. British Journal of Cancer, 1999, 80, 1150-1155.	2.9	150
3	PIK3CAcancer mutations display gender and tissue specificity patterns. Human Mutation, 2008, 29, 284-288.	1.1	120
4	Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. Seminars in Cancer Biology, 2015, 35, 3-10.	4.3	120
5	Genistein blocks breast cancer cells in the G2M phase of the cell cycle. Journal of Cellular Biochemistry, 2000, 79, 594-600.	1.2	115
6	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 2013, 12, 1679-1687.	1.3	109
7	Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Letters, 1998, 130, 143-152.	3.2	103
8	Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Research and Treatment, 2011, 127, 601-610.	1.1	88
9	Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer, 2009, 9, 409.	1.1	81
10	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Clinical Cancer Research, 2016, 22, 337-345.	3.2	58
11	Metabolic Footprints and Molecular Subtypes in Breast Cancer. Disease Markers, 2017, 2017, 1-19.	0.6	52
12	Extracellular matrix proteins as diagnostic markers of breast carcinoma. Journal of Cellular Physiology, 2018, 233, 6280-6290.	2.0	49
13	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. Seminars in Cancer Biology, 2017, 44, 106-116.	4.3	47
14	Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. European Journal of Cancer & Clinical Oncology, 1991, 27, 970-972.	0.9	45
15	miR-30e* is an independent subtype-specific prognostic marker in breast cancer. British Journal of Cancer, 2015, 113, 290-298.	2.9	40
16	Subtypeâ€dependent prognostic relevance of an interferonâ€induced pathway metagene in nodeâ€negative breast cancer. Molecular Oncology, 2014, 8, 1278-1289.	2.1	39
17	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2019, 2, 699-707.	2.6	38
18	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory,RAS-BRAFwild-type colorectal cancer receiving cetuximab or panitumumab. International Journal of Cancer, 2015, 137, 1467-1474.	2.3	33

#	Article	IF	Citations
19	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. Cancers, 2019, 11, 1152.	1.7	33
20	Circulating Biomarkers for Prediction of Treatment Response. Journal of the National Cancer Institute Monographs, 2015, 2015, 60-63.	0.9	31
21	Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. ESMO Open, 2021, 6, 100086.	2.0	31
22	Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. European Journal of Cancer, 1992, 28, 1315-1318.	1.3	30
23	Simultaneous Estimation of Epidermal Growth Factor Receptors and Steroid Receptors in a Series of 136 Resectable Primary Breast Tumors. Tumor Biology, 1988, 9, 200-211.	0.8	29
24	Influence of culture conditions on the estrogenic cell growth stimulation of human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 195-200.	1.2	29
25	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. International Journal of Biological Markers, 2015, 30, 429-433.	0.7	26
26	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. Seminars in Cancer Biology, 2020, 60, 344-350.	4.3	26
27	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. Cancers, 2021, 13, 2356.	1.7	26
28	Selective modulation of ER-? by estradiol and xenoestrogens in human breast cancer cell lines. Cellular and Molecular Life Sciences, 2003, 60, 567-576.	2.4	25
29	Prospective evaluation of estrogen receptor-Î² in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocrine-Related Cancer, 2004, 11, 761-770.	1.6	25
30	Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. International Journal of Molecular Sciences, 2020, 21, 1475.	1.8	25
31	Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines. Anticancer Research, 1995, 15, 2551-5.	0.5	25
32	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models. Cells, 2019, 8, 683.	1.8	21
33	Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3752-3753.	0.8	20
34	Gene Expression Profiling of Circulating Tumor Cells in Breast Cancer. Clinical Chemistry, 2015, 61, 278-289.	1.5	19
35	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers, 2019, 11, 980.	1.7	18
36	Relationship between ER-ICA and conventional steroid receptor assays in human breast cancer. Breast Cancer Research and Treatment, 1986, 8, 35-43.	1.1	17

#	Article	IF	Citations
37	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. International Journal of Cancer, 2020, 146, 3495-3503.	2.3	17
38	int-2 Oncogene amplification and prognosis in node-negative breast carcinoma. , 1997, 74, 620-624.		16
39	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocrine-Related Cancer, 2008, 15, 439-449.	1.6	16
40	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	3.2	16
41	Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients. Journal of Experimental and Clinical Cancer Research, 2022, 41, 78.	3.5	15
42	Prognostic Significance of Progesterone Receptors Alone or in Association with Estrogen Receptors in Human Breast Cancer. Tumori, 1984, 70, 159-164.	0.6	14
43	Adjunctive Medroxyprogesterone Acetate to Radical Nephrectomy in Category M(0) Renal Cell Carcinoma. European Urology, 1983, 9, 202-206.	0.9	13
44	Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Research and Treatment, 1993, 26, 7-13.	1.1	13
45	Modulation of estrogen receptor-Î² isoforms by phytoestrogens in breast cancer cells. International Journal of Oncology, 2006, 28, 1185.	1.4	13
46	Cell cycle dependent oscillatory expression of estrogen receptor-Î± links Pol II elongation to neoplastic transformation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9561-9566.	3.3	13
47	Clinical Significance of Early Changes inÂCirculating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma1. Bladder Cancer, 2016, 2, 395-403.	0.2	13
48	Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods. Disease Markers, 2017, 2017, 1-11.	0.6	13
49	Distribution of Estrogen and Progesterone Receptors in Primary Tumor and Lymph Nodes in Individual Patients with Breast Cancer. Tumori, 1984, 70, 165-168.	0.6	12
50	Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells. Annals of Oncology, 2018, 29, 1599-1601.	0.6	12
51	Modulation of estrogen receptor-beta isoforms by phytoestrogens in breast cancer cells. International Journal of Oncology, 2006, 28, 1185-91.	1.4	12
52	Re: Tamoxifen May Be an Effective Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status. Journal of the National Cancer Institute, 2003, 95, 629-630.	3.0	11
53	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. PLoS ONE, 2015, 10, e0123194.	1.1	11
54	Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma. Clinical Chemistry, 2022, 68, 691-701.	1.5	11

#	Article	IF	Citations
55	Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. Anticancer Research, 1990, 10, 1699-705.	0.5	11
56	Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors. Cancer Research, 1986, 46, 4278s-4281s.	0.4	11
57	TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. Tumori, 2018, 104, 401-405.	0.6	10
58	Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors. Advances in Experimental Medicine and Biology, 2017, 994, 83-103.	0.8	10
59	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. PLoS ONE, 2014, 9, e86511.	1.1	10
60	In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays. Oncotarget, 2016, 7, 976-994.	0.8	10
61	Modulation of Cathepsin-D and pS2 Protein Levels in Human Breast Cancer Cell Lines. Tumor Biology, 1996, 17, 290-298.	0.8	9
62	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. Cancers, 2021, 13, 1409.	1.7	9
63	Paracrine interaction in co-culture of hormone-dependent and independent breast cancer cells. Breast Cancer Research and Treatment, 1993, 26, 275-281.	1.1	8
64	Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert Review of Clinical Pharmacology, 2021, 14, 261-268.	1.3	8
65	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clinical Cancer Research, 2021, 27, 6307-6313.	3.2	8
66	Prognostic significance of progesterone receptors alone or in association with estrogen receptors in human breast cancer. Tumori, 1984, 70, 159-64.	0.6	8
67	Progesterone receptor determination in human breast tumors by immunocytochemical and biochemical techniques. Breast Cancer Research and Treatment, 1989, 14, 217-225.	1.1	7
68	Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer. Microarrays (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td	1.4	7
69	Activity of Tamoxifen and Its Metabolites on Endocrine-Dependent and Endocrine-Independent Breast Cancer Cells. Tumor Biology, 1991, 12, 149-158.	0.8	6
70	Questioning the Utility of Pooling Samples in Microarray Experiments with Cell Lines. International Journal of Biological Markers, 2006, 21, 67-73.	0.7	6
71	Prognostic and functional role of subtypeâ€specific tumorâ€“stroma interaction in breast cancer. Molecular Oncology, 2017, 11, 1399-1412.	2.1	6
72	A combination of extracellular matrixâ€and interferonâ€associated signatures identifies highâ€grade breast cancers with poor prognosis. Molecular Oncology, 2021, 15, 1345-1357.	2.1	6

#	Article	IF	Citations
73	Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. Breast, 2017, 35, 63-68.	0.9	5
74	Clusterin: A potential target for improving response to antiestrogens. International Journal of Oncology, 1992, 33, 791.	1.4	4
75	Interaction between hormone-dependent and hormone-independent human breast cancer cells. European Journal of Cancer & Clinical Oncology, 1991, 27, 1154-1157.	0.9	3
76	Strategies to Translate Preclinical Information to Breast Cancer Patient Benefit. Journal of the National Cancer Institute Monographs, 2011, 2011, 55-59.	0.9	3
77	Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs. Advances in Experimental Medicine and Biology, 2020, 1220, 81-91.	0.8	3
78	Distribution of estrogen and progesterone receptors in primary tumor and lymph nodes in individual patients with breast cancer. Tumori, 1984, 70, 165-8.	0.6	3
79	Genistein blocks breast cancer cells in the G2M phase of the cell cycle. , 2000, 79, 594.		2
80	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. Journal of Clinical Oncology, 2013, 31, 1014-1014.	0.8	2
81	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. JCO Precision Oncology, 2022, 6, e2100472.	1.5	2
82	A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15637-e15637.	0.8	1
83	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 196.	1.8	0
84	Gene Profiles in Breast Cancer. , 2019, , 351-361.		0
85	Advances in Renal Cancer: Arguments Against Hormone Therapy. , 1985, , 311-314.		0
86	Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools. , 2008, , 15-32.		0